Parkinson s disease

LE WE PMID CA

Parkinson s disease

1829

Parkinson Erkrankung

Alzheimer s disease

Amyloid precursor protein

Anandamide

Androgens (Hypogonadotropic hypogonadism)

ATP13A2

Autonomous nervous system (Autonomic neuropathy)

Autophagy

Basal ganglia

Bioinformatics

Carbonyl cyanide m chlorophenylhydrazone CCCP

Cleft plate

CNS (Astrocyte)

CNS (Cerebral cortex)

CNS (Deep brain stimulation)

CNS (Electrotherapy)

CNS (Extrapyramidal diseases)

CNS (Stroke BASKET)

Cognitive behavior therapy

Cybrid

DJ1

Drooling

Dyskinesia (tardive)

Entacapone

FGF Fibroblast growth factor

FGF10

FGF14

FGF20

FGF23

FGF3

FGF8

FGF9

Glucocorticoids

Gluconeogenesis

HtrA2 Omi

Hypophosphatemic ricketts

Lacrimo auriculo dento digital syndrome

Levodopa

Lewy body

LRRK2

Manganese

Methamphetamin

Michel aplasia

Mitochondria (BASKET)

Mitochondria (Dysfunction)

Mitochondria (Fission and Fusion)

Mitochondria (Uncoupling)

Mitophagy

MPTP

Multiple sclerosis

Multiple system atrophy

Neurodegeneration

Neuronal network (Neurophysiology)

Pallidotomy

Parkinson s disease

Pesticides

PINK1

Pramipexole

PRKN

Progressive supranuclear palsy

Quetiapine

Rasagiline

Regeneration of tissues and other biologic structures

Rivastigmin

Ropinirole

Salivary gland (Malformation)

Simulation of biological processes (Bioinformatics)

SNCA

Spinocerebellar ataxia

Statin

Synuclein

Tolcapone

Tremor (BASKET)

TRPV1

Uric acid

Zonisamide

1995 1	Drug treatment of Parkinson's disease. [7888935] BMJ 310(6979): 575-9 (1995)
1996 2	Drug therapy for Parkinson's disease. [8790306] South Med J 89(9): 851-6 (1996)
2005 3	Parkinson's disease: the first common neurological disease due to auto-intoxication? [15728403] QJM 98(3): 215-26 (2005)
2005 4	Parkinson's disease: aetiology, diagnosis, and management. [16340025] Hong Kong Med J 11(6): 476-89 (2005)
2007 5	Glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson's disease. [17471304] Acta Med Okayama 61(2): 51-6 (2007)
2002 6	Catechol-O-methyltransferase and Parkinson's disease. [11873938] Acta Med Okayama 56(1): 1-6 (2002)
2008 7	Parkinson disease: not just a movement disorder. [19088004] Cleve Clin J Med 75(12): 856-64 (2008)
2007 8	Parkinson disease: managing a complex, progressive disease at all stages. [17506237] Cleve Clin J Med 74(5): 313-4, 317-8, 320-2 passim (2007)
2006 9	Utility of tolcapone in fluctuating Parkinson's disease. [18046910] Clin Interv Aging 1(4): 317-25 (2006)
2006 10	Approach to diagnosis of Parkinson disease. [16893149] Can Fam Physician 52(): 862-8 (2006)
2006 11	Parkinson disease. Changing concepts and treatments. [16893139] Can Fam Physician 52(-): 829-30, 835-6 (2006)
2009 12	Update on ropinirole in the treatment of Parkinson's disease. [19557097] Neuropsychiatr Dis Treat 5(-): 33-6 (2009)
2008 13	Current approaches to the treatment of Parkinson's disease. [19043519] Neuropsychiatr Dis Treat 4(4): 743-57 (2008)
2008 14	Update on the use of pramipexole in the treatment of Parkinson's disease. [18728740] Neuropsychiatr Dis Treat 4(2): 337-52 (2008)
2008 15	COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features. [18728767] Neuropsychiatr Dis Treat 4(1): 1-9 (2008)
2007 16	Rivastigmine for the treatment of dementia associated with Parkinson's disease. [19300613] Neuropsychiatr Dis Treat 3(6): 775-83 (2007)
2006 17	Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. [17015225] Neuron 52(1): 33-8 (2006)
2003 18	Parkinson's disease: mechanisms and models. [12971891] Neuron 39(6): 889-909 (2003)
2001 19	Parkinson's disease: clinical signs and symptoms, neural mechanisms, positron emission tomography, and therapeutic interventions. [11530892] Neural Plast 8(1-2): 99-110 (2001)
2009 20	Pathogenesis of familial Parkinson's disease: new insights based on monogenic forms of Parkinson's disease. [19780902] J Neurochem 111(5): 1075-93 (2009)
2008 21	Mitochondrial alterations in Parkinson's disease: new clues. [18680555] J Neurochem 107(2): 317-28 (2008)
2006 22	Modifications of the iron-neuromelanin system in Parkinson's disease. [16417570] J Neurochem 96(4): 909-16 (2006)
1998 23	Neurochemical and neurogenetic correlates of Parkinson's disease. [9721714] J Neurochem 71(3): 893-902 (1998)
2007 24	Catechol-O-methyltransferase and its inhibitors in Parkinson's disease. [17894650] CNS Drug Rev 13(3): 352-79 (2007)
2008 25	Impulse-control disorders in Parkinson's disease. [18704024] CNS Spectr 13(8): 690-8 (2008)
2007 26	Balancing short-term symptom control and long-term functional outcomes in patients with Parkinson's disease. [17426665] CNS Spectr 12(4): 275-86 (2007)
2006 27	Non-motor aspects of Parkinson's disease. [16816793] CNS Spectr 11(7): 541-54 (2006)
2006 28	Lessons learned in deep brain stimulation for movement and neuropsychiatric disorders. [16816792] CNS Spectr 11(7): 521-36 (2006)
2009 29	The emerging role of autophagy in Parkinson's disease. [19754977] Mol Brain 2(): 29 (2009)
2007 30	The 6-hydroxydopamine model of Parkinson's disease. [17449457] Neurotox Res 11(3-4): 151-67 (2007)
2007 31	Inflammation as a causative factor in the aetiology of Parkinson's disease. [17339843] Br J Pharmacol 150(8): 963-76 (2007)
2000 32	The parkinsonian models: invertebrates to mammals. [11138723] Jpn J Pharmacol 84(3): 237-43 (2000)
2010 33	Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson's disease. [20694135] Core Evid 5(-): 1-10 (2010)
2008 34	Progress in the pathogenesis and genetics of Parkinson's disease. [18426756] Philos Trans R Soc Lond B Biol Sci 363(1500): 2215-27 (2008)
2010 35	Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease. [20423607] BMB Rep 43(4): 233-44 (2010)
2010 36	The role of neuroinflammation on the pathogenesis of Parkinson's disease. [20423606] BMB Rep 43(4): 225-32 (2010)
2008 37	Parkinson's disease--Part 3: Neuropsychiatric symptoms. [18402509] Am J Manag Care 14(2 Suppl): S59-69 (2008)
2008 38	Parkinson's disease--Part 2: Treatment of motor symptoms. [18402508] Am J Manag Care 14(2 Suppl): S49-58 (2008)
2008 39	Parkinson's disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment. [18402507] Am J Manag Care 14(2 Suppl): S40-8 (2008)
2003 40	Update on Parkinson disease. [12693888] Ann Intern Med 138(8): 651-8 (2003)
2008 41	A critical evaluation of the Braak staging scheme for Parkinson's disease. [19067353] Ann Neurol 64(5): 485-91 (2008)
2008 42	Central role of alpha-synuclein oligomers in neurodegeneration in Parkinson disease. [19064744] Arch Neurol 65(12): 1577-81 (2008)
2006 43	Phenotypic commonalities in familial and sporadic Parkinson disease. [16606772] Arch Neurol 63(4): 579-83 (2006)
2006 44	Implications of genetics on the diagnosis and care of patients with Parkinson disease. [16533959] Arch Neurol 63(3): 328-34 (2006)
2005 45	Double-blind, placebo-controlled trials for surgical interventions in Parkinson disease. [16157740] Arch Neurol 62(9): 1343-4 (2005)
2005 46	Subthalamic nucleus vs globus pallidus interna deep brain stimulation, the rematch: will pallidal deep brain stimulation make a triumphant return? [15824249] Arch Neurol 62(4): 533-6 (2005)
2005 47	Molecular pathogenesis of Parkinson disease. [15767499] Arch Neurol 62(3): 353-7 (2005)
2004 48	Initial Parkinson disease therapy: levodopa, dopamine agonists, or both? [15596625] Arch Neurol 61(12): 1972-3 (2004)
2004 49	Dopamine agonists modify the course of Parkinson disease. [15596624] Arch Neurol 61(12): 1969-71 (2004)
2004 50	Initial treatment of Parkinson disease: levodopa or dopamine agonists. [15596623] Arch Neurol 61(12): 1966-9 (2004)
2001 51	Surgery for Parkinson disease and other movement disorders: benefits and limitations of ablation, stimulation, restoration, and radiation. [11735770] Arch Neurol 58(12): 1970-2 (2001)
2001 52	Subthalamic deep brain stimulation: neurobehavioral concerns. [11493159] Arch Neurol 58(8): 1205-6 (2001)
2000 53	Surgery for Parkinson disease: A critical evaluation of the state of the art. [10927791] Arch Neurol 57(8): 1118-25 (2000)
1999 54	Stereotactic pallidotomy in the treatment of Parkinson disease: an expert opinion. [10488806] Arch Neurol 56(9): 1064-9 (1999)
1999 55	New and emerging therapies for Parkinson disease. [10404979] Arch Neurol 56(7): 785-90 (1999)
1999 56	Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. [10328247] Arch Neurol 56(5): 529-35 (1999)
1999 57	Diagnostic criteria for Parkinson disease. [9923759] Arch Neurol 56(1): 33-9 (1999)
2008 58	Ubiquitination of alpha-synuclein and autophagy in Parkinson's disease. [18216494] Autophagy 4(3): 372-4 (2008)
2008 59	The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. [18187492] Brain 131(Pt 8): 1969-78 (2008)
2004 60	Biomarkers and Parkinson's disease. [15215212] Brain 127(Pt 8): 1693-705 (2004)
2000 61	The pedunculopontine nucleus and Parkinson's disease. [10960043] Brain 123 ( Pt 9)(-): 1767-83 (2000)
1999 62	Neuropsychological outcome following unilateral pallidotomy. [10581217] Brain 122 ( Pt 12)(-): 2209-20 (1999)
1999 63	Unilateral pallidotomy for advanced Parkinson's disease. [10094248] Brain 122 ( Pt 3)(-): 381-2 (1999)
1964 64	CRYOTHALAMECTOMY FOR PARKINSON'S DISEASE. [14201235] Calif Med 101(-): 248-52 (1964)
1969 65	L-dopa therapy in Parkinson's disease: a critical review of nine years' experience. [4903690] Can Med Assoc J 101(13): 59-68 (1969)
2007 66	Mitochondrial dysfunction in Parkinson's disease. [17464321] Cell Death Differ 14(7): 1261-6 (2007)
1998 67	Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. [10203692] Cell Death Differ 5(10): 832-7 (1998)
2004 68	How does parkin ligate ubiquitin to Parkinson's disease? [15229644] EMBO Rep 5(7): 681-5 (2004)
2008 69	Current management of the cognitive dysfunction in Parkinson's disease: how far have we come? [18535172] Exp Biol Med (Maywood) 233(8): 941-51 (2008)
2008 70	Emerging pathways in genetic Parkinson's disease: Potential role of ceramide metabolism in Lewy body disease. [19021754] FEBS J 275(23): 5767-73 (2008)
2005 71	Molecular pathogenesis of Parkinson's disease. [16126732] Hum Mol Genet 14(18): 2749-55 (2005)
2004 72	Parkin genetics: one model for Parkinson's disease. [14976155] Hum Mol Genet 13 Spec No 1(-): R127-33 (2004)
2002 73	Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. [12351575] Hum Mol Genet 11(20): 2395-407 (2002)
1999 74	The genetics of disorders with synuclein pathology and parkinsonism. [10469843] Hum Mol Genet 8(10): 1901-5 (1999)
1995 75	Parkinson's disease: from etiology to treatment. [8774962] Intern Med 34(11): 1045-54 (1995)
2005 76	Subthalamic stimulation for Parkinson's disease. [16011063] Isr Med Assoc J 7(7): 458-63 (2005)
2006 77	Diagnosis and treatment of Parkinson disease: molecules to medicine. [16823471] J Clin Invest 116(7): 1744-54 (2006)
2005 78	STN stimulation and neuroprotection in Parkinson's disease--when beautiful theories meet ugly facts. [16107346] J Neurol Neurosurg Psychiatry 76(9): 1186-7 (2005)
2005 79	Neurodegenerative disorders: Parkinson's disease and Huntington's disease. [16024878] J Neurol Neurosurg Psychiatry 76(8): 1058-63 (2005)
2005 80	Cholinesterase inhibitors for treatment of dementia associated with Parkinson's disease. [15965192] J Neurol Neurosurg Psychiatry 76(7): 903-4 (2005)
2005 81	Beyond the holy grail of motor symptoms: deep brain stimulation for Parkinson's disease. [15897490] J Neurol Neurosurg Psychiatry 76(6): 759-60 (2005)
2005 82	Targeting the subthalamic nucleus for deep brain stimulation: technical approach and fusion of pre- and postoperative MR images to define accuracy of lead placement. [15716537] J Neurol Neurosurg Psychiatry 76(3): 409-14 (2005)
2004 83	Early pathological changes in the parkinsonian brain. [14966144] J Neurol Neurosurg Psychiatry 75(3): 352 (2004)
2000 84	Dopamine agonists: their role in the treatment of Parkinson's disease. [10811688] J Neurol Neurosurg Psychiatry 68(6): 685-9 (2000)
1997 85	Surgery for Parkinson's disease. [9010390] J Neurol Neurosurg Psychiatry 62(1): 2-8 (1997)
1996 86	How far are we in understanding the cause of Parkinson's disease? [8676157] J Neurol Neurosurg Psychiatry 61(1): 4-16 (1996)
1994 87	Parkinson's disease. [7755681] J Neurol Neurosurg Psychiatry 57(6): 672-81 (1994)
1989 88	The on-off phenomenon. [2666577] J Neurol Neurosurg Psychiatry Suppl(-): 29-37 (1989)
1989 89	Clues to the mechanism underlying dopamine cell death in Parkinson's disease. [2666576] J Neurol Neurosurg Psychiatry Suppl(-): 22-8 (1989)
1989 90	Is "Parkinson's disease" one disease? [2666575] J Neurol Neurosurg Psychiatry Suppl(-): 18-21 (1989)
1989 91	Current theories on the cause of Parkinson's disease. [2666574] J Neurol Neurosurg Psychiatry Suppl(-): 13-7 (1989)
1981 92	Speech disorders of Parkinsonism: a review. [7031185] J Neurol Neurosurg Psychiatry 44(9): 751-8 (1981)
2001 93	Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. [11724917] Mol Pathol 54(6): 414-8 (2001)
2001 94	The aetiology of idiopathic Parkinson's disease. [11724911] Mol Pathol 54(6): 369-80 (2001)
2004 95	Neuroimaging in Parkinson's disease. [15717025] NeuroRx 1(2): 243-54 (2004)
2004 96	Genetics of Parkinson disease. [15717024] NeuroRx 1(2): 235-42 (2004)
2004 97	Neurodegeneration and neuroprotection in Parkinson disease. [15717014] NeuroRx 1(1): 139-54 (2004)
2004 98	Molecules that cause or prevent Parkinson's disease. [15547643] PLoS Biol 2(11): e401 (2004)
2004 99	Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. [15299154] Postgrad Med J 80(946): 452-8 (2004)
2003 100	Neuropsychiatric non-motor aspects of Parkinson's disease. [14612597] Postgrad Med J 79(936): 561-5 (2003)
2000 101	Pharmacological treatment of Parkinson's disease. [11009573] Postgrad Med J 76(900): 602-10 (2000)
1997 102	Parkinson's disease. [9196696] Postgrad Med J 73(859): 257-64 (1997)
1992 103	Parkinson's disease. [1437950] Postgrad Med J 68(801): 538-43 (1992)
1988 104	Accuracy in the clinical diagnosis of parkinsonian syndromes. [3059338] Postgrad Med J 64(751): 345-51 (1988)
1977 105	The treatment of Parkinson's disease. [343079] Postgrad Med J 53(626): 729-31 (1977)
1977 106	Symptomatic Parkinsonism. [343078] Postgrad Med J 53(626): 726-8 (1977)
1977 107	Physiology of abnormal movements. [343077] Postgrad Med J 53(626): 713-8 (1977)
1977 108	The biochemistry of the basal ganglia and Parkinson's disease. [24209] Postgrad Med J 53(626): 719-25 (1977)
1972 109	Augmenting the action of levodopa. [4568331] Postgrad Med J 48(565): 653-6 (1972)
1971 110	Current concepts of Parkinsonism. [4945017] Postgrad Med J 47(554): 794-9 (1971)
1996 111	Parkinson's disease. Diagnosis and treatment. [8987437] West J Med 165(4): 234-40 (1996)
1994 112	Treatment of Parkinson's disease. [7975571] West J Med 161(3): 303-8 (1994)
1974 113	Parkinson's disease and levodopa. A five-year follow-up and review. [4606887] West J Med 121(3): 188-206 (1974)
2003 114	Are ubiquitination pathways central to Parkinson's disease? [12859888] Cell 114(1): 1-8 (2003)
2004 115	alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease. [15135042] FEBS Lett 565(1-3): 1-5 (2004)
2008 116	Visual signs and symptoms of Parkinson's disease. [18271776] Clin Exp Optom 91(2): 129-38 (2008)
2004 117	CNS dopamine oxidation and catechol-O-methyltransferase: importance in the etiology, pharmacotherapy, and dietary prevention of Parkinson's disease. [14767563] Int J Mol Med 13(3): 343-53 (2004)
2006 118	Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. [16953112] Exp Mol Med 38(4): 333-47 (2006)
2006 119	Recognition and management of neuropsychiatric complications in Parkinson's disease. [17146092] CMAJ 175(12): 1545-52 (2006)
2003 120	Current concepts in the diagnosis and management of Parkinson's disease. [12566335] CMAJ 168(3): 293-301 (2003)
2011 121	Neuropharmacological approach against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine)-induced mouse model of Parkinson's disease. [21731080] Acta Neurobiol Exp (Wars) 71(2): 269-80 (2011)
2008 122	Animal models of Parkinson's disease progression. [18273623] Acta Neuropathol 115(4): 385-98 (2008)
2009 123	Neuropsychiatry of Parkinson's disease. [19838536] Arq Neuropsiquiatr 67(3B): 930-9 (2009)
2011 124	Positron emission tomography neuroimaging in Parkinson's disease. [21904653] Am J Transl Res 3(4): 323-41 (2011)
2007 125	Parkinson's disease. [17762036] BMJ 335(7617): 441-5 (2007)
2010 126	Tickled PINK1: mitochondrial homeostasis and autophagy in recessive Parkinsonism. [19595762] Biochim Biophys Acta 1802(1): 20-8 (2010)
2010 127	Mitochondrial trafficking of APP and alpha synuclein: Relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases. [19619643] Biochim Biophys Acta 1802(1): 11-9 (2010)
2008 128	Redox imbalance in Parkinson's disease. [18358848] Biochim Biophys Acta 1780(11): 1362-7 (2008)
2010 129	Towards model-based control of Parkinson's disease. [20368246] Philos Transact A Math Phys Eng Sci 368(1918): 2269-308 (2010)
2009 130	Mitochondrial dysfunction and biogenesis in the pathogenesis of Parkinson's disease. [20035637] Chang Gung Med J 32(6): 589-99 (2009)
2009 131	Methamphetamine-induced neurotoxicity: the road to Parkinson's disease. [20081231] Pharmacol Rep 61(6): 966-77 (2009)
2005 132	Present and future drug treatment for Parkinson's disease. [16227533] J Neurol Neurosurg Psychiatry 76(11): 1472-8 (2005)
2004 133	Use and interpretation of on/off diaries in Parkinson's disease. [14966154] J Neurol Neurosurg Psychiatry 75(3): 396-400 (2004)
2007 134	Role of deep brain stimulation targeted to the pedunculopontine nucleus in Parkinson's disease. [17563240] Expert Rev Neurother 7(6): 585-9 (2007)
2008 135	CBT for the treatment of depression in Parkinson's disease: a promising nonpharmacological approach. [18088199] Expert Rev Neurother 8(1): 27-35 (2008)
2010 136	Parkinson's disease: insights from pathways. [20421364] Hum Mol Genet 19(R1): R21-7 (2010)
2007 137	Parkinson's disease. [17911161] Hum Mol Genet 16 Spec No. 2(-): R183-94 (2007)
2010 138	Levodopa in the treatment of Parkinson's disease: an old drug still going strong. [20852670] Clin Interv Aging 5(-): 229-38 (2010)
2010 139	The role of rasagiline in the treatment of Parkinson's disease. [20517484] Clin Interv Aging 5(-): 149-56 (2010)
2010 140	Imaging approaches to Parkinson disease. [20351351] J Nucl Med 51(4): 596-609 (2010)
2010 141	Astrocytes and therapeutics for Parkinson's disease. [20880505] Neurotherapeutics 7(4): 413-23 (2010)
2009 142	LRRK2 in Parkinson's disease: in vivo models and approaches for understanding pathogenic roles. [19804414] FEBS J 276(22): 6445-54 (2009)
2008 143	Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease. [18342017] Free Radic Biol Med 44(11): 1873-86 (2008)
2011 144	Available and emerging treatments for Parkinson's disease: a review. [21607020] Drug Des Devel Ther 5(-): 241-54 (2011)
2009 145	The retina in Parkinson's disease. [19336464] Brain 132(Pt 5): 1128-45 (2009)
2004 146	Progress in clinical neurosciences: Parkinson's disease with dementia and dementia with Lewy bodies. [15038467] Can J Neurol Sci 31(1): 7-21 (2004)
2010 147	Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis. [20945982] Biomark Med 4(5): 701-12 (2010)
2011 148	Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: implications for patients. [21654875] Neuropsychiatr Dis Treat 7(-): 297-302 (2011)
2008 149	Drugs for Parkinson’s disease: levodopa is still the gold standard. [18728800] Neuropsychiatr Dis Treat 4(1): i-ii (2008)
2009 150	From genes to proteins in mendelian Parkinson's disease: an overview. [19943343] Anat Rec (Hoboken) 292(12): 1893-901 (2009)
2010 151	3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. [20837848] Arch Neurol 67(9): 1062-7 (2010)
2005 152	Transient receptor potential vanilloid subtype 1 mediates cell death of mesencephalic dopaminergic neurons in vivo and in vitro. [15659603] J Neurosci 25(3): 662-71 (2005)
2010 153	Quetiapine in the treatment of psychosis in Parkinson's disease. [21179595] Ther Adv Neurol Disord 3(6): 339-50 (2010)
2010 154	Pharmacotherapy in Parkinson's disease: case studies. [21179604] Ther Adv Neurol Disord 3(2): 117-26 (2010)
2010 155	Treatment of dysautonomia in extrapyramidal disorders. [21180636] Ther Adv Neurol Disord 3(1): 53-67 (2010)
2009 156	Therapeutic options for continuous dopaminergic stimulation in Parkinson's disease. [21180645] Ther Adv Neurol Disord 2(2): 105-13 (2009)
2009 157	Cellular repair strategies in Parkinson's disease. [21180641] Ther Adv Neurol Disord 2(1): 51-60 (2009)
2009 158	A review of the use of zonisamide in Parkinson's disease. [21180621] Ther Adv Neurol Disord 2(5): 313-7 (2009)
2009 159	Targeting the progression of Parkinson's disease. [19721815] Curr Neuropharmacol 7(1): 9-36 (2009)
2009 160	Parkinson disease: systemic and orofacial manifestations, medical and dental management. [19491161] J Am Dent Assoc 140(6): 658-69 (2009)
2008 161	Genetic neuropathology of Parkinson's disease. [18784814] Int J Clin Exp Pathol 1(3): 217-31 (2008)
2008 162	Diagnosis and management of Parkinson's disease dementia. [18822028] Int J Clin Pract 62(10): 1581-7 (2008)
2010 163	Prevalence, classification, and etiology of pain in Parkinson's disease: association between Parkinson's disease and fibromyalgia or chronic widespread pain. [20805678] Tohoku J Exp Med 222(1): 1-5 (2010)
2011 164	Manganese and Parkinson's disease: a critical review and new findings. [22124833] Cien Saude Colet 16(11): 4519-66 (2011)
2011 165	Clinical problems in the hospitalized Parkinson's disease patient: systematic review. [21284037] Mov Disord 26(2): 197-208 (2011)
2011 166	Rapidly progressive diffuse Lewy body disease. [21484863] Mov Disord 26(7): 1316-23 (2011)
2010 167	DJ-1, PINK1, and their effects on mitochondrial pathways. [20187230] Mov Disord 25 Suppl 1(-): S44-8 (2010)
2008 168	Pathophysiology of parkinsonism. [18467168] Clin Neurophysiol 119(7): 1459-74 (2008)
2009 169	Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review. [19298613] CNS Neurosci Ther 15(2): 157-82 (2009)
2011 170	Management of the hospitalized patient with Parkinson's disease: current state of the field and need for guidelines. [21159538] Parkinsonism Relat Disord 17(3): 139-45 (2011)
2011 171	Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease. [21423589] Patient Prefer Adherence 5(-): 57-64 (2011)
2008 172	Pathophysiology and treatment of psychosis in Parkinson's disease: a review. [18665659] Drugs Aging 25(8): 665-82 (2008)
2010 173	The genetics of Parkinson disease. [20938043] J Geriatr Psychiatry Neurol 23(4): 228-42 (2010)
2008 174	Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria? [17680806] Genes Brain Behav 7(2): 129-51 (2008)
2004 175	A reality test: How well do we understand psychosis in Parkinson's disease? [14990754] J Neuropsychiatry Clin Neurosci 16(1): 8-18 (2004)
2009 176	The cybrid model of sporadic Parkinson's disease. [19328199] Exp Neurol 218(2): 320-5 (2009)
2009 177	Mitochondrial dynamics in Parkinson's disease. [19332061] Exp Neurol 218(2): 247-56 (2009)
2010 178	Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. [19913097] Neurobiol Dis 37(3): 510-8 (2010)
2010 179	A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PD. [20921515] Neurology 75(14): 1292-9 (2010)
2010 180	Persistent organochlorine pesticides in serum and risk of Parkinson disease. [20350979] Neurology 74(13): 1055-61 (2010)
2010 181	Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? [20368634] Neurology 74(14): 1143-8 (2010)
2011 182	Prospects of statins in Parkinson disease. [21252380] Neuroscientist 17(3): 244-55 (2011)
2010 183	Unravelling the role of defective genes. [20696314] Prog Brain Res 183(-): 43-57 (2010)
2010 184	Pathophysiological roles for purines: adenosine, caffeine and urate. [20696321] Prog Brain Res 183(-): 183-208 (2010)
2010 185	Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. [20696322] Prog Brain Res 183(-): 209-33 (2010)
2010 186	Genetic animal models of Parkinson's disease. [20547124] Neuron 66(5): 646-61 (2010)
2010 187	Parkinson's disease as a disconnection syndrome. [20383586] Neuropsychol Rev 20(2): 191-208 (2010)
2005 188	Neuroimaging and therapeutics in movement disorders. [15897956] NeuroRx 2(2): 361-71 (2005)
2005 189	Genetic mouse models of parkinsonism: strengths and limitations. [16389313] NeuroRx 2(3): 495-503 (2005)
2005 190	Toxin-induced models of Parkinson's disease. [16389312] NeuroRx 2(3): 484-94 (2005)
2009 191	Prevalence and definition of drooling in Parkinson's disease: a systematic review. [19288042] J Neurol 256(9): 1391-6 (2009)
2011 192	Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease? [21244648] Mol Neurodegener 6(1): 6 (2011)
2010 193	Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease. [20388210] Mol Neurodegener 5(-): 14 (2010)
2011 194	Pharmacological and physiological characterization of the tremulous jaw movement model of parkinsonian tremor: potential insights into the pathophysiology of tremor. [21772815] Front Syst Neurosci 5(-): 49 (2011)
2011 195	Tracking extranigral degeneration in animal models of Parkinson's disease: quest for effective therapeutic strategies. [21615738] J Neurochem 118(3): 326-38 (2011)
2007 196	Mitochondrial dysfunction in Parkinson's disease--revisited. [17530578] Neurol Neurochir Pol 41(2): 150-9 (2007)
2010 197	Cross-talk between mitochondria and proteasome in Parkinson's disease pathogenesis. [20577640] Front Aging Neurosci 2(-): 17 (2010)
2011 198	Treatment of advanced Parkinson's disease. [21331376] Parkinsons Dis 2010(-): 480260 (2011)
2011 199	The endotoxin-induced neuroinflammation model of Parkinson's disease. [21331154] Parkinsons Dis 2011(-): 487450 (2011)
2011 200	New thoughts on thought disorders in Parkinson's disease: review of current research strategies and challenges. [21403865] Parkinsons Dis 2011(-): 675630 (2011)
2011 201	Models for LRRK2-Linked Parkinsonism. [21603132] Parkinsons Dis 2011(-): 942412 (2011)
2011 202	Lipopolysaccharide animal models for Parkinson's disease. [21603177] Parkinsons Dis 2011(-): 327089 (2011)
2011 203	Peripheral inflammation increases the damage in animal models of nigrostriatal dopaminergic neurodegeneration: possible implication in Parkinson's disease incidence. [21603178] Parkinsons Dis 2011(-): 393769 (2011)
2011 204	Optimizing a rodent model of Parkinson's disease for exploring the effects and mechanisms of deep brain stimulation. [21603182] Parkinsons Dis 2011(-): 414682 (2011)
2011 205	Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy? [21603186] Parkinsons Dis 2011(-): 689181 (2011)
2011 206	Mitochondrial contribution to Parkinson's disease pathogenesis. [21687805] Parkinsons Dis 2011(-): 159160 (2011)
2011 207	Genetic mutations and mitochondrial toxins shed new light on the pathogenesis of Parkinson's disease. [21860779] Parkinsons Dis 2011(-): 979231 (2011)
2010 208	Feasibility of using cranial electrotherapy stimulation for pain in persons with Parkinson's disease. [20976091] Parkinsons Dis 2010(-): 569154 (2010)
2011 209	Parkinson's disease mouse models in translational research. [21559878] Mamm Genome 22(7-8): 401-19 (2011)
2009 210	Molecular pathology of the fibroblast growth factor family. [19621416] Hum Mutat 30(9): 1245-55 (2009)
2009 211	Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. [19165601] Apoptosis 14(4): 478-500 (2009)
2009 212	Mitochondrial dysfunction in mouse models of Parkinson's disease revealed by transcriptomics and proteomics. [19967437] J Bioenerg Biomembr 41(6): 487-91 (2009)
2009 213	Mitochondrial quality control: insights on how Parkinson's disease related genes PINK1, parkin, and Omi/HtrA2 interact to maintain mitochondrial homeostasis. [20012177] J Bioenerg Biomembr 41(6): 473-9 (2009)
2010 214	Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next? [21126348] BMC Med 8(): 80 (2010)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Parkinson s disease.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Parkinson s disease.php on line 92